Gastric Cancer – Page 2

PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade

By MedXY 11/07/2025

Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 blockade restores antitumour immunity in preclinical models, supporting biomarker‑driven combination trials.

Gastroenterology news Oncology

Menopausal Hormone Therapy and Reduced Risk of Upper Gastrointestinal Cancers: Insights From a Large Nordic Population Study

By MedXY 10/08/2025

A large Nordic study finds menopausal hormone therapy reduces the risk of esophageal and gastric cancers by up to 30%, especially with combined estrogen-progestin systemic formulations.

Clinical Updates news Oncology Specialties

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Anesthesiology General Surgery news Nursing & care Oncology Specialties

Electroacupuncture Significantly Shortens Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: Insights from a Multicenter Randomized Trial

By MedXY 08/26/2025

This multicenter randomized trial demonstrates that electroacupuncture reduces postoperative ileus duration and accelerates gastrointestinal recovery after laparoscopic gastrectomy for gastric cancer, outperforming sham and standard care.

Clinical Updates news Oncology Specialties

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations

By MedXY 08/05/2025

A comprehensive meta-analysis confirms that Helicobacter pylori eradication reduces gastric cancer risk and related deaths, especially benefiting high-risk groups, supporting widespread screening and treatment.

Medical News news Oncology Specialties

Is Your Practice Missing the Next Gastric Cancer Surge?

By MedXY 08/03/2025

A new study predicts 11.8 million gastric cancer cases linked to Helicobacter pylori infection among children born 2008-2017, urging stronger global prevention and vaccine development.

Clinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

news Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.